{
    "clinical_study": {
        "@rank": "16779", 
        "arm_group": [
            {
                "arm_group_label": "Subcutaneous Enoxaparin", 
                "arm_group_type": "Active Comparator", 
                "description": "Subcutaneous enoxaparin 40 mg every 24 hours for three days"
            }, 
            {
                "arm_group_label": "Intravenous Enoxaparin", 
                "arm_group_type": "Active Comparator", 
                "description": "40 mg enoxaparin daily as continuous intravenous infusion for three days (72 hours)"
            }
        ], 
        "brief_summary": {
            "textblock": "To evaluate the pharmacokinetics of the thromboprophylactic agent enoxaparin in critically\n      ill patients by comparing plasma anti-factor Xa activity when enoxaparin is administered\n      either as a continuous intravenous infusion or subcutaneous bolus once daily.\n\n      To investigate possible ongoing coagulation by coagulation markers during antithrombotic\n      therapy with standard doses of enoxaparin"
        }, 
        "brief_title": "Pharmacokinetics of Enoxaparin in Intensive Care Patients", 
        "condition": "Venous Thromboembolism", 
        "condition_browse": {
            "mesh_term": [
                "Thromboembolism", 
                "Venous Thromboembolism", 
                "Venous Thrombosis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age: 18 to 70 years\n\n          -  Body Mass Index between 18-30 kg/m2\n\n          -  Critically ill patients requiring intensive care and pharmacological\n             thromboprophylaxis\n\n          -  Expected to remain in the ICU for at least 72 h\n\n          -  Written informed consent obtained from the patient or his/her legal representative.\n\n        Exclusion Criteria:\n\n          -  Other indications for anticoagulant therapy than thromboprophylaxis\n\n          -  Intracranial haemorrhage or central neurosurgical operation within three months prior\n             to the admission\n\n          -  Disseminated intravascular coagulation (DIC) according to the international society\n             on Thrombosis and Haemostasis criteria\n\n          -  Known heparin induced thrombocytopenia (HIT), or hypersensitivity to enoxaparin or\n             heparin\n\n          -  Treatment with enoxaparin or any other low-molecular weight heparin (LMWH) or heparin\n             within 24 hours prior to ICU admission. If patient has received thromboprophylactic\n             dose of LMWH within 24-72 hours before ICU admission inclusion can be done if\n             measured anti-factor Xa level is <0.1 IU/ml at the time of admission\n\n          -  Any long-term anticoagulant medication, expect low-dose aspirin\n\n          -  Major bleeding within the last week unless definitively treated\n\n          -  Blood platelet count <50, P-thromboplastin time (TT) <40% , international normalized\n             ratio (INR) >1.7\n\n          -  Glomerular filtration rate less than 50 ml/min/1.73 m2 estimated from serum\n             creatinine by applying Cockcroft-Gault equation  or chronic dialysis\n\n          -  HIV, hepatitis B virus, or hepatitis C virus infection\n\n          -  Pregnancy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 18, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02095509", 
            "org_study_id": "2012-004599-21"
        }, 
        "intervention": {
            "arm_group_label": [
                "Subcutaneous Enoxaparin", 
                "Intravenous Enoxaparin"
            ], 
            "description": "Drug class: Low-molecular weight heparin", 
            "intervention_name": "Enoxaparin", 
            "intervention_type": "Drug", 
            "other_name": "Klexane (sanofi-Aventis Oy, Finland)"
        }, 
        "intervention_browse": {
            "mesh_term": "Enoxaparin"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 20, 2014", 
        "location": [
            {
                "contact": {
                    "email": "anne.kuitunen@pshp.fi", 
                    "last_name": "Anne Kuitunen, PhD", 
                    "phone": "+358 3 311 65544"
                }, 
                "facility": {
                    "address": {
                        "city": "Tampere", 
                        "country": "Finland", 
                        "state": "Pirkanmaa", 
                        "zip": "33521"
                    }, 
                    "name": "Tampere University Hospital"
                }, 
                "investigator": {
                    "last_name": "Annukka Yl\u00f6nen, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "miia.valkonen@hus.fi", 
                    "last_name": "Miia Valkonen, PhD"
                }, 
                "facility": {
                    "address": {
                        "city": "Helsinki", 
                        "country": "Finland", 
                        "state": "Uusimaa", 
                        "zip": "00029"
                    }, 
                    "name": "Helsinki University Central Hospital, Meilahti"
                }, 
                "investigator": {
                    "last_name": "Miia Valkonen, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Finland"
        }, 
        "number_of_arms": "2", 
        "overall_contact": {
            "email": "anne.kuitunen@pshp.fi", 
            "last_name": "Anne Kuitunen, PhD", 
            "phone": "+358 3 311 65544"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Finland: Finnish Medicines Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Change in plasma anti-factor Xa levels between baseline and 72 hours", 
            "measure": "Plasma anti-factor Xa level", 
            "safety_issue": "Yes", 
            "time_frame": "72 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02095509"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "If clinically suspected a compression ultrasound will be done", 
                "measure": "Incidence of Venous thromboembolism", 
                "safety_issue": "Yes", 
                "time_frame": "90 days"
            }, 
            {
                "description": "Major and minor bleeding events will be reported", 
                "measure": "Incidence of Bleeding", 
                "safety_issue": "Yes", 
                "time_frame": "90 days"
            }
        ], 
        "source": "Tampere University Hospital", 
        "sponsors": {
            "collaborator": {
                "agency": "Helsinki University Central Hospital", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Tampere University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}